| Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH | Frank Vinluan | 01/28/20 | Boston |
| Advanced Therapies Are Reshaping Biopharma R&D: KPMG Report | Gareth Macdonald | 01/28/20 | National |
| Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More | Sarah de Crescenzo | 01/24/20 | National |
| Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & More | Frank Vinluan | 01/17/20 | National |
| FDA Panel Votes Down Nektar Opioid Painkiller, Asks for More Data | Frank Vinluan | 01/14/20 | National |
| Biotech Roundup: Drug Pricing Promises, Bone Disease Data, IPO Plans & More | Sarah de Crescenzo | 01/10/20 | National |
| Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More | Frank Vinluan | 01/03/20 | National |
| Bio Roundup: Amarin’s Approval, FTC v. Illumina, a $120M Deal & More | Sarah de Crescenzo | 12/20/19 | National |
| Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More | Frank Vinluan | 12/13/19 | National |
| KalVista Pharma Eye Drug Partnered With Merck Flunks Phase 2 Test | Frank Vinluan | 12/10/19 | Boston |
| FDA Rejects Enzyvant’s Regenerative Therapy for Rare Immune Disorder | Frank Vinluan | 12/05/19 | Boston |
| Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More | Frank Vinluan | 11/22/19 | National |
| Biopharma Execs Remain Optimistic Despite Political Headwinds | Mike Ward | 11/20/19 | National |
| Bio Roundup: Feds Sue Gilead, Biogen Eyes China, CRISPR’d Kidneys & More | Frank Vinluan | 11/08/19 | National |
| AstraZeneca Chooses China for R&D and AI Centers, $1B Biotech Fund | Gareth Macdonald | 11/06/19 | National |
| GE Healthcare Opens Startup Labs at Former AstraZeneca UK R&D Site | Dan Stanton | 11/06/19 | National |
| Biotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & More | Frank Vinluan | 11/01/19 | National |
| FDA Halts Novartis Gene Therapy Study Amid Animal Safety Concerns | Frank Vinluan | 10/30/19 | National |
| Bio Roundup: Biogen’s Reversal, FDA Moves Fast, a CF Cocktail & More | Sarah de Crescenzo | 10/25/19 | National |
| Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More | Frank Vinluan | 10/18/19 | National |
| FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades | Frank Vinluan | 10/11/19 | Indiana |
| Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More | Alex Lash | 10/11/19 | National |
| The Placebo Effect Is Hobbling New Psychiatric Drugs. What Can Stop It? | Alex Lash | 10/10/19 | National |
| Five Years After Y Combinator First Admits Biotechs, They’re Dug In | Bernadette Tansey | 10/09/19 | San Francisco |
| Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels | Frank Vinluan | 10/07/19 | National |
| Bio Roundup: PARP Progress, A New Commish, IPO-Palooza & More | Ben Fidler | 10/04/19 | National |
| ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More | Ben Fidler | 10/01/19 | National |
| Dova Pharmaceuticals Agrees to Sobi Acquisition, Shares Jump 38% | Frank Vinluan | 09/30/19 | Raleigh Durham |
| Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More | Frank Vinluan | 09/27/19 | National |
| Bio Roundup: Pelosi’s Reveal, Alder’s Deal, Biogen’s Fails & More | Alex Lash | 09/20/19 | National |
